1+MG / B1MG Stakeholder Forum

Overview of the B1MG Maturity level model

13th October 2022

Astrid Vicente (Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal)

Slido: **SF2022**

1+MG Trust Framework

Genomics Data

Assessment for Healthcare

Slido: **SF2022**

B1MG WP5 - Personalised Medicine delivery, scientific and societal impact

Opportunity to consider implementation and sustainability

- How effectively are healthcare systems using genomic information?
- What are the bottlenecks and challenges?
- What are the best practices/common tools we can share?
- How can adoption by healthcare systems be improved?



B1MG Maturity Level Model: what is it?

What is it?

A tool for healthcare systems to self-evaluate the level of maturity of their genomic medicine practices according to a **common matrix**, and to define a path to optimization

Aim

Promote and facilitate the adoption of genomics in healthcare systems to make personalised medicine accessible to citizens and patients across Europe.



Slido: **SF2022**

B1MG Maturity Level Model development and validation



Delphi survey

- 21 high level experts invited
- 14 experts completed the validation
- Welphi online platform
- Launched in July 2021

B1MG Maturity Level Model

Where are you on your journey?



B1MG Maturity Level Model
currently available on B1MG website.

Slido: **SF2022**

B1MG Maturity Level Model pilot

Pilot in real life settings - national/regional healthcare systems

- Assess feasibility
- Stimulate discussion among stakeholders across European health systems
- Address transferability of Best Practices
- Address development of an action plan for progress towards optimization



Slido: **SF2022**

B1MG Maturity Level Model ToolKit

B1MG MLM ToolKit:

- B1MG MLM
- User Guide
- Assessment tool



Slido: **SF2022**

B1MG Maturity Level Model pilot analysis

Data analysis

- Identify the areas of **strengths and weaknesses in each domain**
- Use this information to set goals, define areas of investment and **develop an action plan**



Spider web diagram - self-assessment outcomes for Domain II (hypothetical)

Slido: **SF2022**

B1MG Maturity Level Model cross-Europe analysis

Domain II_Investment and economic model



Domain VII_Clinical genomics guidelines and infrastructure



- What domains/indicators are consistently strong/weak across countries?
- Where are the strong asymmetries across countries?
- Which domains/indicators need more investment?
- In which domains is progress easier, where are the bottlenecks for progression?

Slido: **SF2022**

B1MG Maturity Level Model pilot survey



- Overall, this exercise was helpful to understand the way forward regarding genomic medicine in healthcare.
- The B1MG MLM framework is useful to establish an action plan for the future.



- Will your country/region use the outcomes of this exercise to develop a detailed Action Plan for genomic medicine in healthcare and establish maturity goals based on the MLM?
- Will the MLM be helpful to monitor the Action Plan?
- Will a network of countries be helpful to share practices on establishing and implementing an Action Plan?

Slido: **SF2022**

B1MG Maturity Level Model conclusions

- Developed and validated a **tool for the assessment of genomic maturity in healthcare systems**
- Formed a **network** for sharing best practices
- Analysing best practices, challenges and asymmetries in pilot countries across Europe to issue **recommendations**
- B1MG MLM as a **sustainability tool**, allowing assessment of maturity, but also development and monitoring of action plans for optimization.

Slido: **SF2022**

Beyond B1MG one Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724

Slido: **SF2022**

WP5 Team

Astrid Vicente (INSA), Serena Scollen (ELIXIR Hub), Ilse Custers (Lygature)

Thank you !!

slido

Audience Q&A Session

ⓘ Start presenting to display the audience questions on this slide.